MLTX · Nasdaq · CIK 0001821586

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics’s most recent SEC filing in our snapshot is a Form 8-K filed on Sep 30, 2026. Its EDGAR record lists 27 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$227.3M
Form 4 filings on record, past 12 months
27

Company overview

Legal name (as filed)
MoonLake Immunotherapeutics
Ticker
MLTX
SEC Central Index Key (CIK)
0001821586
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
ZUG, Switzerland
State or country of incorporation
Cayman Islands
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#2387 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from MoonLake Immunotherapeutics’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$4.5MFY2021-$50.0MFY2022-$36.0MFY2023-$118.9MFY2024-$227.3MFY2025
MLTX annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-$4.5M-$50.0M-$36.0M-$118.9M-$227.3M
Diluted EPS-$0.31-$1.70-$0.73-$1.89-$3.53
Total assets$9.7M$76.8M$526.5M$477.9M$424.4M
Cash and equivalents$8.0M$39.5M$451.2M$180.4M$334.5M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareBasicAndDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

MLTX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Feb 25, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Sep 30, 20268-KOther events· period Sep 30, 2026Document · Index
Apr 21, 2026DEF 14ADefinitive proxy statement· period Jun 4, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about MoonLake Immunotherapeutics, by form type:

4 ×158-K ×8144 ×3SCHEDULE 13G/A ×310-Q ×2424B5 ×2SCHEDULE 13G ×1S-8 ×1S-3ASR ×1SCHEDULE 13D/A ×1ARS ×1DEFA14A ×1DEF 14A ×1
MLTX recent filings
FiledFormWhat it isOriginal
Sep 30, 20268-KOther events· period Sep 30, 2026Document · Index
Aug 14, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 10, 2026S-8REGISTRATION STATEMENTDocument · Index
Aug 10, 2026S-3ASRREGISTRATION STATEMENTDocument · Index
Aug 10, 20268-KResults of operations; Regulation FD disclosure· period Aug 10, 2026Document · Index
Jul 29, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 27, 2026Document · Index
Jul 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 21, 2026Document · Index
Jul 21, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 20, 2026Document · Index
Jul 20, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026Document · Index
Jul 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 15, 20268-KOther events· period Jul 14, 2026Document · Index
Jul 13, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 9, 2026Document · Index
Jul 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jun 30, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 29, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jun 25, 20268-KMaterial agreement· period Jun 23, 2026Document · Index
Jun 24, 2026424B5PROSPECTUS SUPPLEMENTDocument · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 22, 2026Document · Index
Jun 22, 2026424B5PRELIMINARY PROSPECTUS SUPPLEMENTDocument · Index
Jun 22, 20268-KRegulation FD disclosure; Other events· period Jun 21, 2026Document · Index
Jun 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 17, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 17, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 17, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 17, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 17, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 17, 2026Document · Index
Jun 17, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026Document · Index
Jun 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 9, 20268-KDirector or officer change; Shareholder vote results· period Jun 4, 2026Document · Index
Jun 1, 20268-KMaterial agreement· period May 22, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 13, 20264Statement of changes in beneficial ownership (insider trade)· period May 11, 2026Document · Index
May 11, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 11, 20268-KResults of operations; Regulation FD disclosure· period May 10, 2026Document · Index
Apr 21, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 21, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 21, 2026DEF 14ADefinitive proxy statement· period Jun 4, 2026Document · Index

Insider filing activity

27 Form 4 filings appear in MoonLake Immunotherapeutics’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001821586 and XBRL company facts. MoonLake Immunotherapeutics on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.